Kevin Kelly, MD
Pain Medicine · Hyannis, MANPI 1225024656
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,449 of the $7,069 with a category attached, or 77.1%. 40 manufacturers reported payments, led by Medtronic at 48.2% of the total. Reporting peaked in 2019 at $2,181 and has fallen 57.9% since, to $919 in 2025.
Across 198 payments — averaging $35.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Nevro Corp.$334
- Scilex Pharmaceuticals Inc.$258
- Boston Scientific$255
- Vertex$245
- Stimwave Technologies Incorporated$229
- plus $2K from 34 others
Across 1 payment — averaging $1230.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
What the payments were for
- Travel & lodging$1,62023%
- Food & beverage$5,44977%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 59 | $3,404 |
| Nevro Corp. | 7 | $334 |
| Scilex Pharmaceuticals Inc. | 16 | $258 |
| Boston Scientific | 9 | $255 |
| Vertex | 6 | $245 |
| Stimwave Technologies Incorporated | 3 | $229 |
| Pacira Therapeutics, Inc. | 8 | $213 |
| AbbVie | 9 | $213 |
| Biohaven Pharmaceuticals, Inc. | 5 | $193 |
| Amgen | 6 | $192 |
| Biodelivery Sciences International, Inc. | 11 | $136 |
| Painteq LLC | 2 | $119 |
| Abbott | 4 | $116 |
| Relievant Medsystems, Inc. | 2 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $100 |
| Nalu Medical, Inc. | 4 | $72 |
| Vertos Medical, Inc. | 3 | $71 |
| Stryker | 3 | $69 |
| Novartis | 3 | $66 |
| Pfizer | 4 | $62 |
| Almatica Pharma LLC | 2 | $55 |
| Zimmer Biomet | 1 | $50 |
| Spinal Simplicity, LLC | 2 | $47 |
| GRT US Holding, Inc. | 2 | $46 |
| Averitas Pharma Inc. | 2 | $44 |
| Redhill Biopharma Inc. | 2 | $44 |
| Assertio Therapeutics, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $32 |
| Si-bone, Inc. | 1 | $32 |
| Tersera Therapeutics LLC | 2 | $29 |
| Baudax Bio Inc. | 2 | $29 |
| Bioventus LLC | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| MML US, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Avanos Medical | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Merz North America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$1,153
- SYNCHROMEDII$560
- VANTA ADAPTIVESTIM$175
- JOURNAVX$125
- NURTEC ODT$124
- Senza Spinal Cord Stimulation System$100
How this compares
$7,069 in reported general payments places this provider in the 80th percentile of 137 pain medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 24 | $9,521 |
| Gabapentin | 128 | $1,533 |
| Lidocaine | 11 | $903 |
| Celecoxib | 30 | $513 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $351 |
| Duloxetine Hcl | 24 | $296 |
| Cyclobenzaprine Hcl | 30 | $257 |
| Tramadol Hcl | 12 | $224 |
| Meloxicam | 42 | $133 |
| Cephalexin | 18 | $78 |
| Oxycodone Hcl | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $20 | $9,52124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 137 pain medicine providers in Massachusetts.
Other pain medicine in Hyannis
- Hariharan SundramNewton$1.7M
- Thomas SimopoulosBoston$181K
- Ivan UritsWareham$70K
- Antje BarreveldNewton$64K
- Arti OriBoston$62K
- Christine SangBoston$56K
- Ali EbrahimiBurlington$41K
- Alexandra AdlerLowell$35K
- Eduard VaynbergBoston$32K
- David GarasNatick$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.